|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Heart, Lung, and Blood Institute (NHLBI) |
|---|---|
| Collaborator: |
Thalassemia Clinical Research Network |
| Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00000623 |
Purpose
The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
| Condition | Intervention |
|---|---|
|
Anemia, Cooley's Beta-Thalassemia Hematologic Diseases Thalassemia Osteoporosis Iron Overload Hypertension, Pulmonary |
Drug: Deferoxamine Drug: Deferiprone Drug: Arginine Drug: Sildenafil Drug: Decitabine |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Thalassemia Clinical Research Network (TCRN) |
| Estimated Enrollment: | 1000 |
| Study Start Date: | July 2000 |
| Study Completion Date: | July 2006 |
Show Detailed Description Eligibility| Ages Eligible for Study: | 1 Year to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Please refer to specific studies for eligibility criteria.
Contacts and Locations| United States, California | |
| Children's Hospital Oakland | |
| Oakland, California, United States, 94609 | |
| United States, Massachusetts | |
| Children's Hospital | |
| Boston, Massachusetts, United States, 02115 | |
| United States, New York | |
| Weill Medical College of Cornell University | |
| New York, New York, United States, 10021 | |
| United States, Pennsylvania | |
| Children's Hospital of Philadelphia | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Canada, Ontario | |
| Toronto General Hospital | |
| Toronto, Ontario, Canada, M5G 2C4 | |
| Principal Investigator: | Alan R. Cohen, MD | Children's Hospital of Philadelphia |
| Principal Investigator: | Patricia J. Giardina, MD | Weill Medical College of Cornell University |
| Principal Investigator: | Ellis J. Neufeld, MD, PhD | Children's Hospital Medical Center, Cincinnati |
| Principal Investigator: | Nancy F. Olivieri, MD | Toronto General Hospital |
| Principal Investigator: | Elliott P. Vichinsky, MD | Children's Hospital & Research Center Oakland |
| Principal Investigator: | Sonja McKinlay, PhD | New England Research Institutes, Inc. |
More Information
| ClinicalTrials.gov Identifier: | NCT00000623 History of Changes |
| Other Study ID Numbers: | 317, U01 HL65232, U01 HL65233, U01 HL65238, U01 HL65239, U01 HL65244, U01 HL65260 |
| Study First Received: | October 27, 1999 |
| Last Updated: | November 29, 2007 |
| Health Authority: | United States: Federal Government |
|
chelator iron transfusion anemia thalassemia |
|
Anemia Beta-Thalassemia Hematologic Diseases Hypertension Hypertension, Pulmonary Osteoporosis Thalassemia Iron Overload Anemia, Hemolytic, Congenital Anemia, Hemolytic Hemoglobinopathies Genetic Diseases, Inborn Vascular Diseases Cardiovascular Diseases Lung Diseases |
Respiratory Tract Diseases Bone Diseases, Metabolic Bone Diseases Musculoskeletal Diseases Iron Metabolism Disorders Metabolic Diseases Deferoxamine Deferiprone Decitabine Sildenafil Siderophores Iron Chelating Agents Chelating Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
